Here is a selection of this week's latest news from around the world
 |
 |
|
Takeda shareholders back £46bn Shire takeoverTakeda Pharmaceutical has won shareholder approval for a £46bn ($59bn) takeover of UK-listed drugmaker Shire, clearing the way for Japan's largest corporate acquisition. To read more follow this BBC News link |
Janssen unveils new data backing wider use of DarzalexJanssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma. To read more follow this PharmaTimes link |
|
 |
 |
|
Johnson & Johnson pays $300m to develop cusatuzumabJohnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies. To read more follow this PharmaTimes link |
ASH18: CAR-T shows up in early CLL testA CAR-T cell therapy acquired by Celgene earlier this year could have a path forward in chronic lymphocytic leukemia (CLL), showing initial signs of efficacy in a small group of heavily pretreated patients with the blood cancer. To read more follow this BioPharmaDive link |
|
 |
 |
|
Eli Lilly's former drug yields Phase 2 win for Vanda PharmaVanda Pharmaceuticals on Monday rolled out positive Phase 2 data supporting its experimental drug for gastroparesis, a condition that's gone without new treatment options for nearly four decades. To read more follow this BioPharmaDive link |
|
Roche's Hemlibra shows sustained bleed control in childrenRoche's Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A. To read more follow this BioPharmaDive link |
| For more Regulatory Index news click here |